EDP Biotech, New Day Diagnostics to Merge

Original from: 360DX

EDP Biotech and New Day Diagnostics announced on Wednesday that they will combine their assets to form a new company. 

The new company will retain the New Day Diagnostics name, and both companies' teams will unite under a unified leadership structure based in Knoxville, Tennessee, the firms said in a statement. EDP Biotech CEO and President Eric Mayer will serve as president and CEO of the combined company, while New Day Founder and CEO Navroze Mehta will serve as executive chairman of the new firm.

EDP Biotech has developed the ColoPlex multiplexed immunoassay test for early detection of colorectal cancer and precancerous polyps and offers contract research organization services to multiple diagnostic companies. The firm also operates a CLIA laboratory that provides business-to-business and direct-to-consumer testing, research, and validation services.

Boca Raton, Florida-based New Day Diagnostics offers the direct-to-consumer Biocard Celiac Disease Self-Test, as well as tests for infectious diseases, ovarian cancer, and prostate cancer.

"This strategic marriage will allow us to continue delivering innovative and cost-effective diagnostic solutions, making a profound impact on patient care and outcomes including the underserved population and uninsured patients," Mayer said in a statement. 

​

Source: EDP Biotech, New Day Diagnostics to Merge